Alvotech to Release First-Quarter 2026 Financial Results on May 6
Alvotech said it will release first-quarter 2026 financial results on May 6, 2026, and host a webcast with live Q&A on May 7. The company said five biosimilars are already approved and marketed, with nine disclosed candidates in development.
Alvotech announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST).
Slides and other material will be made available on its investor website before the call.
Alvotech is a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept) and Prolia/Xgeva (denosumab).
The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. The company has formed a network of strategic commercial partnerships in markets that include the United States, Europe, Japan, China, other Asian countries, and large parts of South America, Africa and the Middle East.